Search the Newsreel

RTW Investments (QURE) discloses 3.94M-share beneficial stake in uniQure N.V.

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 3,941,572 Ordinary Shares of uniQure N.V. (QURE), representing a 5.7% stake in the company. This disclosure was made in a SCHEDULE 13G filing, indicating a passive investment. The percentage is calculated …

Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71

Stifel has reiterated its Buy rating for UniQure NV (QURE.US), maintaining its target price at $71. This indicates continued confidence from Stifel in the company's stock performance.

Uniqure NV (QURE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE

Hennion & Walsh Asset Management Inc. significantly increased its stake in uniQure N.V. (QURE) by 107.3% during the second quarter, acquiring an additional 73,566 shares and bringing their total holding to 142,113 shares valued at approximately $6.55 million. Despite this increased institutional interest, uniQure …

Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE

Assenagon Asset Management S.A. significantly increased its stake in uniQure N.V. (NASDAQ:QURE) by 249.9% in the second quarter, now holding 513,530 shares valued at approximately $23.65 million. Despite missing quarterly earnings estimates, uniQure, a biotechnology company focused on gene therapies, maintains a "Moderate Buy" …

Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path

uniQure N.V. (QURE) saw its stock rise by 6.4% following FDA alignment for an accelerated approval pathway for its Huntington's disease gene therapy, AMT-130. Despite a wider net loss in the last quarter, this regulatory development, coupled with a recent $259 million capital raise, …

UniQure N.V. (QURE) Stock Analysis: Exploring A 53.35% Potential Upside In Gene Therapy

uniQure N.V. (QURE) is a biotechnology company focused on gene therapies for rare diseases, with analysts projecting a 53.35% potential upside. Despite being in a developmental phase with negative P/E and free cash flow, the company shows positive technical indicators and a strong product …

Uniqure NV (QURE) Stock News Today

uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages

uniQure N.V. (NASDAQ:QURE) has received an average "Moderate Buy" rating from analysts, with 13 out of 17 analysts recommending a buy, and an average 12-month price target of $65.00 against its current $45.36 share price. Recent analyst actions include price target increases from Wells …

Understanding the Setup: (QURE) and Scalable Risk

Uniqure N.v. (NASDAQ: QURE) shows strong near-term sentiment with a neutral mid and long-term outlook, operating within a mid-channel oscillation pattern. The article details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. It also highlights an exceptional …

Mayur Uniquoters Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Mayur Uniquoters Q1 net profit jumps 43% to ₹58.95 crore; EBITDA margin expands

Mayur Uniquoters Share: லாபம் **43%** உயர்வு! பங்குதாரர்களுக்கு டிவிடெண்ட் அறிவிப்பு!

Mayur Uniquoters fixes Aug 21 as dividend record date for FY26

UniQure: Q2 Earnings Snapshot

This article provides a brief "Q2 Earnings Snapshot" for UniQure. Due to the limited content, specific financial details are not available.

uniQure N.V. Stock 12‑Month Price Target Raised to $66.08, Implies 80% Upside

uniQure N.V.'s average 12-month stock price target has been increased to $66.08, up from $64.83, based on estimates from 12 analysts. This new target suggests an 80% potential upside from its July 28 closing price. The consensus rating for uniQure N.V. remains a "Buy" …

uniQure (QURE) Stock Rises On Cash Runway Despite Deepening Losses

H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $80

H.C. Wainwright has reiterated its Buy rating for UniQure NV (QURE.US) and maintained a target price of $80. This indicates the firm's continued confidence in the company's financial prospects and stock performance.

QURE Maintained by Wells Fargo -- Price Target Raised to $75

Wells Fargo maintained its Overweight rating for uniQure (QURE)

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

uniQure (QURE) reported a wider-than-expected loss of $1.22 per share in Q2 2026, due to increased non-operating expenses, despite an 11% year-over-year rise in revenues to $5.8 million, which still missed estimates. The company is advancing its gene therapy AMT-130 for Huntington's disease, with …

uniQure stock upgraded by Wolfe Research on Huntington’s therapy outlook

Wolfe Research has upgraded uniQure BV (NASDAQ: QURE) stock to Outperform from Peerperform, setting a price target of $65.00 due to a stronger outlook for its AMT-130 Huntington’s therapy. The firm models a 70% probability of success for the treatment and projects $2 billion …

uniQure NV (QURE) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Operational Challenges

uniQure NV reported Q2 2026 earnings, showcasing strategic advancements for its AMT-130 program with positive regulatory guidance and promising early data for other initiatives. Despite high R&D and increased SG&A expenses, the company strengthened its balance sheet. Operational challenges remain regarding the confirmatory study …

Uniqure NV earnings missed by $0.38, revenue topped estimates

Uniqure NV reported a Q2 EPS of $-1.220, missing analyst estimates by $0.38, but revenue for the quarter exceeded expectations at $5.84M against an estimated $5.49M. The company's stock has shown strong performance, rising over 91% in the last 3 months and more than …

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) reported a Q2 loss of $1.22 per share, missing the Zacks Consensus Estimate of a loss of $0.81, and revenues of $5.84 million, also below estimates. Despite missing earnings and revenue expectations for the quarter, the stock has seen a 53.2% gain …

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure reported its second-quarter 2026 financial results, highlighting significant progress in its gene

uniQure N.V. 2026: Revenue $5.84M, EPS ($1.22) — 10-Q Summary

uniQure N.V. reported its Q2 2026 financial results, with revenue of $5.84M but a wider net loss of ($81.06M) and diluted EPS of ($1.22), compared to the prior year. Despite the increased net loss, the company highlighted revenue growth, positive clinical trial data for …

Earnings Flash (QURE) UniQure N.V. Reports Q2 Revenue $5.8M, Vs. FactSet Est of $5.5M

UniQure N.V. (QURE) has reported its second-quarter revenue of $5.8 million, surpassing FactSet's estimated revenue of $5.5 million. This indicates a stronger financial performance than anticipated for the quarter.

uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.40 EPS

uniQure N.V. Revenue Breakdown – NASDAQ:QURE

uniQure N.V. (NASDAQ: QURE) reported a revenue of $16.10 million USD last year. This figure primarily originated from its Innovative Gene Therapies segment, which was also the top-performing segment. The current year's revenue for this segment is a decrease from the previous year's $27.12 …

Uniqure NV (QURE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Uniqure NV (QURE), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings. Additionally, it lists ETFs with …

uniQure Q2 2026 Earnings Preview

* uniQure (QURE [https://seekingalpha.com/symbol/QURE]) is scheduled to announce Q2 earnings results on Wednesday, July 29th, before market open. * The consensus EPS estimate is -$0.81 [https://seekingalpha.com/symbol/QURE/earnings/estimates] and the consensus revenue estimate is $5.38M (+2.3% Y/Y). * Over the last 3 months, EPS estimates have …

Mayur Uniquoters hosts Q1FY27 earnings call on Aug 6

Uniqure NV (QURE) Income Statement

This article provides the quarterly and annual income statements for Uniqure NV (QURE), offering financial insights into the company's performance. It details key metrics such as total revenue, cost of revenue, operating expenses, and net income over several fiscal quarters and years, along with …